According to a new market research report "Companion Diagnostics Market Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022", published by MarketsandMarkets™, The global companion diagnostic market is expected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%.

Browse 105 market data Tables and 37 Figures spread through 170 Pages and in-depth TOC on "Companion Diagnostics Market”
http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html
Early buyers will receive 10% customization on this report.

The global companion diagnostics market is expected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of the market can be attributed to increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the companion diagnostics market. However, the uncertainty in the reimbursement scenario in different countries is expected to hinder market growth.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=155571681

In this report, the market is segmented on the basis of product & service, technology, indication, end user, and region. On the basis of product & service, the assay kits & reagents segment accounted for the largest share in 2016, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.

Based on technology, the polymerase chain reaction segment accounted for the largest share in 2016. The large share of this segment can be attributed to the advantages of PCR such as its ease of use and easy availability of kits & reagents with a quick turnaround time as compared to other technologies.

Based on indication, the companion diagnostics market is further categorized into oncology, infectious diseases, neurology, and other indications (including cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field.

Download Sample Pages of this Report: http://www.marketsandmarkets.com/requestsample.asp?id=155571681

On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This end-user segment is also expected to grow at the highest CAGR during the forecast period. The largest share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.

Geographically, the companion diagnostics market in the Asia-Pacific region is expected to witness the highest CAGR during the forecast period, owing to the growing need for tailored therapeutics by the elderly population; increasing number of hospitals and diagnostic laboratories; and growing prevalence of life-threatening diseases.

As NGS technology has a significant impact on the growth of the companion diagnostics market, major market players are focusing on undertaking strategic developments for developing companion diagnostics products based on the NGS technology.
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators and strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441